Lamium Pharmaceuticals Private Limited

Founded in 2017 and headquartered in Maharashtra, India.

2017 | Pune, Maharashtra (India) | Active
Last Updated:

Lamium Pharmaceuticals Profile

Key Indicators

  • Authorised Capital ₹ 0.10 M
  • Paid Up Capital ₹ 0.10 M
  • Company Age 7 Year, 6 Months
  • Last Filing with ROC 31 Mar 2023
  • Revenue Growth 33.26%
  • Profit Growth 616.58%
  • Ebitda 200.09%
  • Net Worth 260.39%
  • Total Assets 95.23%

About Lamium Pharmaceuticals

Lamium Pharmaceuticals Private Limited (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 November 2017 (Seven years and six months 7 days old ). Its registered office is in Pune, Maharashtra, India.

The Company is engaged in the Pharma Industry.

The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.

Vijaykumar Mangrule and Sadashiv Mangrule serve as directors at the Company.

Company Details

  • Location

    Pune, Maharashtra, India

  • Telephone

    +91-XXXXXXXXXX

  • Email Address

  • Website

  • Social Media

Corporate Identity Details

  • CIN/LLPIN

    U74999PN2017PTC173456

  • Company No.

    173456

  • Company Classification

    Private Limited Indian Non-Government Company

  • Incorporation Date

    17 Nov 2017

  • Date of AGM

    30 Sep 2023

  • Date of Balance Sheet

    31 Mar 2023

  • Listing Status

    Unlisted

  • ROC Code

    Roc Pune

Industry

Pharma
Company report

Lamium Pharmaceuticals Private Limited

Explore comprehensive data for Lamium Pharmaceuticals Private Limited, including financials, compliance details, shareholding patterns, and litigation history.

Who are the key members and board of directors at Lamium Pharmaceuticals?

Board Members (2)

NameDesignationAppointment DateStatus
Vijaykumar Mangrule Country flag representing In Director 17-Nov-2017Current
Sadashiv Mangrule Country flag representing In Director 26-Aug-2021Current

Financial Performance of Lamium Pharmaceuticals.

Lamium Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 33.26% increase. The company also saw a substantial improvement in profitability, with a 616.58% increase in profit. The company's net worth Soared by an impressive increase of 260.39%.

Lamium Pharmaceuticals revenue growth over time
Lamium Pharmaceuticals profit and loss trends over time
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023)YOY Growth
(FY 2022)(FY 2021)(FY 2020)(FY 2019)
Total Revenue
33.26%
Revenue from Operations
33.26%
Total Assets
95.23%
Profit or Loss
616.58%
Net Worth
260.39%
EBITDA
200.09%

What is the Ownership and Shareholding Structure of Lamium Pharmaceuticals?

Unlock access to Lamium Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Indicator graph

Charges (Loans)

Placeholder for charges-related data

There are no open charges registered against the company as per our records.

How Many Employees Work at Lamium Pharmaceuticals?

Unlock and access historical data on people associated with Lamium Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee growth trends for Lamium Pharmaceuticals Private Limited

Deals i

Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Lamium Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lamium Pharmaceuticals's trajectory.

Rating

Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Latest Updates, News, and FAQs on Lamium Pharmaceuticals

Recent activity within the organization

  • Annual General Meeting

    Lamium Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.

  • Balance Sheet

    Lamium Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Pune.

  • Director Appointment

    Sadashiv Ramrao Mangrule was appointed as a Director was appointed as a Director on 26 Aug 2021 & has been associated with this company since 3 years 8 months .

  • Director Appointment

    Vijaykumar Ramrao Mangrule was appointed as a Director was appointed as a Director on 17 Nov 2017 & has been associated with this company since 7 years 6 months .

  • Company Incorporation

    Lamium Pharmaceuticals Private Limited was registered on 17 Nov 2017 with Roc Pune & aged 7 years 6 months as per MCA records.

Frequently asked questions

  • What is the Incorporation or founding date of Lamium Pharmaceuticals Private Limited?

    Lamium Pharmaceuticals Private Limited was incorporated on 17 Nov 2017.

  • What is authorized share capital and paid-up capital of Lamium Pharmaceuticals Private Limited?

    The authorized share capital of Lamium Pharmaceuticals Private Limited is ₹ 0.10 M and paid-up capital is ₹ 0.10 M.

  • Who are the current board members & directors of Lamium Pharmaceuticals Private Limited?

    Currently 2 directors are associated with Lamium Pharmaceuticals Private Limited.

    • Vijaykumar Ramrao Mangrule
    • Sadashiv Ramrao Mangrule

  • What is the registered address of Lamium Pharmaceuticals Private Limited?

    As per Ministry of Corporate Affairs (Mca), the registered address of Lamium Pharmaceuticals Private Limited is 555 Bajare Mala Vadki Haveli India, Pune, Maharashtra, 412307.

  • What is the corporate identification number (CIN) and company number of Lamium Pharmaceuticals Private Limited?

    The corporate identification number (CIN) of Lamium Pharmaceuticals Private Limited is U74999PN2017PTC173456 and the company number is 173456 as per Ministry of Corporate Affairs (MCA).

  • What has been the recent revenue trend for Lamium Pharmaceuticals Private Limited?

    According to the financial reports for the fiscal year 2023, the revenue trend for Lamium Pharmaceuticals Private Limited has risen by 33.26%.

  • What change has been observed in the net worth of Lamium Pharmaceuticals Private Limited, and by what percentage?

    The financial reports for the fiscal year 2023 indicates that The net worth of Lamium Pharmaceuticals Private Limited has experienced an upsurge of 260.39%.

  • When was the last Balance Sheet of Lamium Pharmaceuticals Private Limited filed with the ROC?

    The most recent Balance Sheet for Lamium Pharmaceuticals Private Limited was filed with the ROC on 31 Mar 2023.

Unlock Business Insights – Explore Instantly!

Search company & director profiles for free and gain access to critical business data.

  • 3.1M+ Companies
  • 15M+ Legal Cases
  • 525K+ Credit Ratings
  • 5.8M+ Directors & KMP
  • 750K+ Regulatory Alerts
  • 1.1M+ Companies' Financial Records
Start Free Trial

People also Viewed

Similar Companies Based on Drug Formulation & Development